Tideglusib Clinical Trials
2 recruitingDrug
Phase 22Phase 31
Showing 1–2 of 2 trials
Recruiting
Phase 2
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
Arrhythmogenic CardiomyopathyArrhythmogenic Right Ventricular Cardiomyopathy
Hamilton Health Sciences Corporation120 enrolled17 locationsNCT06174220
Recruiting
Phase 2Phase 3
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Congenital Myotonic Dystrophy
AMO Pharma Limited76 enrolled14 locationsNCT05004129